Company Overview and News
IRVINE, Calif., June 15, 2018 (GLOBE NEWSWIRE) -- Sabra Health Care REIT, Inc. (Nasdaq:SBRA) (Nasdaq:SBRAP) announced today that Harold Andrews, the company’s Chief Financial Officer will be participating in the JMP Securities Boston Real Estate Forum being held June 28th at The Langham in Boston, MA.
We’ll look at some successes, failures, and curious bifurcations that split off the ugly ducklings from the magnificent SWANs.
VTR DDR UE.WI GRT.PRH GRT.PRG UE SBRA 511768 DDR.PRJ SPG.PRJ JBGS DDR.PRK MASTERTR DDR.PRA SPG SMTA CCP SBRAP
IRVINE, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- Sabra Health Care REIT, Inc. (Nasdaq:SBRA) announced today that on June 1, 2018, it completed the previously announced sale of 12 facilities (11 skilled nursing facilities and 1 senior housing community) leased to Genesis Healthcare, Inc. (“Genesis”) located in New Hampshire and Florida for $134.0 million. Under the terms of Sabra’s memoranda of understanding with Genesis, Genesis’s annual rent obligations to Sabra were reduced by $12.
GEN CCP SBRA SBRAP
This article is Update 29 (and the last) to my original article entitled "If I Had to Build An Income Portfolio Today".
GEO UNIT STAG.PRB STAG.PRC EPD TD SBRA STWD.WI VZA CALM WELL STAG TD HASI STAG.PRA SBRAP VTR DOC PEGI RY TNTTF VDE IRM RY ORI CLDT WES PEG VZ STWD OHI
Real estate is an attractive investment category — and also a risky one. Owning physical real estate can provide attractive returns, but a lot can go wrong: tenants can leave in the middle of the night, pipes can burst and markets can change without warning.
KBWY PSA.PRA HCN ROOF PSA.PRB AMT.PRB AMT.PRA WELL.PRI PSA.A SBRA AMT EQR WELL PSAXZ PSA.PRG GGP PSA.PRE MAC PSA.PRF AVB PSA.PRC PSA.PRD VTR PSA.PRY PSA.PRZ PSA.PRW HCN.PRJ PSA.PRX PSA.PRU PSA.PRV HCN.PRI PSA PSA.PRS PSA.PRT SPG.PRJ GNL SPG GNL.PRA WPG
Document Table of Contents UNITED ST
IRVINE, Calif., May 07, 2018 (GLOBE NEWSWIRE) -- Sabra Heath Care REIT, Inc. (Nasdaq:SBRA) (Nasdaq:SBRAP) (“Sabra”, “we” or the “Company”) announced today that it has entered into definitive agreements to restructure the Company’s master leases with its tenant, Signature HealthCARE (“Signature”), including the provision to Signature of working capital in the form of a term loan.
GEN OHI CCP SBRA SBRAP
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
as of ET